Summary
Tirzepatide is a dual GLP-1/GIP agonist approved for type 2 diabetes and obesity. Retatrutide adds a third receptor — glucagon — making it a triple agonist with greater weight loss in Phase 2 trials. This article compares mechanism, evidence, and practical differences.
Quick Comparison
| Retatrutide | Tirzepatide | |
|---|---|---|
| Receptors | GLP-1 + GIP + GCGR (triple) | GLP-1 + GIP (dual) |
| Approval status | Investigational (Phase 3) | Approved (diabetes + obesity in several countries) |
| Dosing | Weekly injection | Weekly injection |
| Max weight loss (trials) | ~24% at 48 weeks (Phase 2) | ~22.5% at 72 weeks (Phase 3) |
| Primary developer | Eli Lilly | Eli Lilly |
| Human safety data | Phase 2 complete | Extensive — post-approval surveillance ongoing |
Mechanism
Tirzepatide
Tirzepatide is a dual agonist: it activates both the GLP-1 receptor and the GIP receptor. Its structure is based on the native GIP peptide, with modifications that also allow it to bind and activate the GLP-1 receptor.
GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion. GIP receptor activation amplifies insulin secretion and may contribute to the central appetite effects. The combination produces greater weight loss than GLP-1 monotherapy alone.
Tirzepatide is manufactured by Eli Lilly under the brand names Mounjaro (diabetes) and Zepbound (obesity), and is approved in the US, EU, and several other regions.
Retatrutide
Retatrutide adds a third receptor: the glucagon receptor (GCGR). Glucagon receptor activation increases energy expenditure and fat oxidation — effects that are distinct from and additive to the satiety and insulin effects of GLP-1/GIP signalling.
The hypothesis behind adding glucagon receptor activity is that while GLP-1/GIP primarily reduces caloric intake, glucagon receptor agonism simultaneously increases caloric burn. The combination of fewer calories in and more calories out may explain why Retatrutide's Phase 2 weight loss data exceeded both GLP-1 monotherapy and dual agonist trials.
Appetite Effects
Both compounds reduce appetite via GLP-1 receptor activation. Tirzepatide's GIP component may add centrally mediated satiety signals. Retatrutide's additional glucagon receptor activity does not directly suppress appetite but reduces energy storage and promotes fat utilisation.
Practically, both compounds produce significant reductions in food intake in clinical trials. Individual responses vary. Some researchers note that Retatrutide's energy expenditure component means weight loss may continue even when appetite suppression is incomplete — a potentially meaningful difference for people who are diet-resistant.
Body Composition Considerations
Both compounds produce weight loss predominantly from fat mass, with some lean mass loss — a known concern with all GLP-1-class compounds. In the Retatrutide Phase 2 trial, approximately 65–75% of weight loss was from fat mass, with 25–35% from lean mass. Similar ratios were seen with Tirzepatide.
Neither compound is specifically designed to preserve muscle mass. Resistance exercise during use is widely discussed among researchers and clinicians as a strategy to maintain lean tissue, though this has not been formally studied in controlled trials with either compound.
Research Status and Evidence Quality
Tirzepatide has substantially more published human data:
- SURPASS Phase 3 programme (type 2 diabetes) — complete
- SURMOUNT Phase 3 programme (obesity) — largely complete
- Post-approval real-world data accumulating since 2022
Retatrutide has:
- Two Phase 2 trials published in NEJM and Lancet (2023)
- Phase 3 trials ongoing
- No post-approval real-world data
For anyone requiring an approved, well-characterised option, Tirzepatide has a substantially deeper evidence base. Retatrutide remains investigational.
Side Effects
Both compounds share the GLP-1 class side effect profile:
- Nausea and vomiting: Most common, especially early in treatment or after dose increases. Typically improves over 2–4 weeks.
- Diarrhoea and constipation: Both occur; the pattern varies by individual.
- Reduced appetite and early satiety: Desired effect but can cause inadequate caloric intake if not monitored.
- Injection site reactions: Mild redness or discomfort in a minority of users.
Retatrutide's glucagon receptor activity adds the theoretical risk of elevated liver enzymes and metabolic perturbations — these were monitored in Phase 2 and no significant safety signals emerged, but Phase 3 data will be more informative.
Both carry a class warning about thyroid C-cell tumours based on rodent data; human clinical significance is not established.
Practical Differences
From a research perspective, the most important practical differences are:
- Availability: Tirzepatide is available by prescription; Retatrutide is only available through clinical trials or research supply channels.
- Evidence certainty: Tirzepatide outcomes are well-characterised over multiple Phase 3 trials. Retatrutide Phase 2 results are impressive but Phase 3 data will be the definitive benchmark.
- Effect magnitude: Based on available data, Retatrutide appears to produce greater weight loss. The clinical significance of this difference will be clearer once Phase 3 results are published.
Who May Discuss Each Option
Tirzepatide is appropriate to discuss with a physician for people with type 2 diabetes or obesity meeting approved criteria. It is a prescription medication.
Retatrutide is appropriate to discuss in the context of formal clinical research or with a physician familiar with investigational compounds. It is not an approved treatment.
Summary
Retatrutide is Tirzepatide's triple-receptor successor. The addition of glucagon receptor activity adds an energy expenditure dimension that Tirzepatide lacks, and Phase 2 weight loss data suggests greater efficacy. Tirzepatide, however, has far more published clinical evidence and is an approved medication with a known safety profile. Retatrutide's Phase 3 programme will determine whether its Phase 2 advantages are confirmed at scale.
Related Topics
Safety & Regulatory Note
Tirzepatide (Mounjaro/Zepbound) is an approved prescription medication in several countries for type 2 diabetes and/or obesity. Retatrutide is an investigational compound that has completed Phase 2 trials and is not yet approved anywhere. Neither should be used without qualified medical supervision.
References
- 1.Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist Retatrutide for obesity — a phase 2 trial. NEJM, 389(6), 514–526.
- 2.Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. NEJM, 387(3), 205–216.
- 3.Frias JP, et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. NEJM, 385(6), 503–515.
- 4.Rosenstock J, et al. (2023). Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, for people with type 2 diabetes. Lancet, 402(10401), 529–544.
